CELGENE - Nach dem Split gehts erst richtig los - 500 Beiträge pro Seite

[jeninvestor]

Celgene WKN:881244

Informationen zu Celgene:

Celgene is a pharmaceutical company encompassing research, development, manufacturing, and sales and marketing. At Celgene, our mission is to employ our strong research capabilities and expertise toward the discovery, development and commercialization of small molecules for cancer and immunological diseases.

(Homepage: www.celgene.com)

Seit dem Split am 17.04.2000 hat der Kurs wieder zugelegt nach dem er wie alle Biotech-Firmen „etwas“ vom Top verloren hatte.

Der Höchstkurs betrug 64,33E, das Tief lag bei 4,57E (innerhalb der letzten 52 Wochen).

Am 11.04.2000 empfahl Morgan Stanley die Aktie zu Kauf und gab ein Kursziel von 212$ an. Das würde rein rechnerisch nach dem Split ein Ziel von ca. 71$ bedeuten.

Die Aktie ist nach der Korrektur und dem Split weiterhin ein klarer Kauf.

Jedoch ist damit zurechnen, das die Biotech-Werte noch einmal mit dem Gesamt-Markt nach unten gehen werden, da die Korrektur noch nicht abgeschlossen ist.

Kurs USA 11.12 OZ: 42 $

[jeninvestor]

Auch wenn es vielleicht niemanden interessiert, hier etwas zum 1.Q



News April 27, 16:43 Eastern Time

Audio: Celgene Reports Better-Than-Expected Q1

Celgene Corporation, a pharmaceutical company focused on the
immunology and oncology markets, reported first quarter losses of 5 cents per
share.

Bis bald

[jeninvestor]

Hier noch was zu den Zahlen:


Der Verlust belief sich auf 3,1 Millionen US-Dollar. Im Vorjahresquartal wurde noch ein Verlust von 6,6 Millionen US-Dollar ausgewiesen.

Die Umsätze konnten von 4,3 Millionen auf 11,9 (+176%) Millionen US-Dollar gesteigert werden. Allein durch die Arznei Thalomid wurde ein Umsatz von 11,7 Millionen US-Dollar generiert.

Die Ausgaben für Forschung und Entwicklung erhöhten sich um 41 Prozent.

Aktueller Stand in USA: 48$ (10.48 OZ)=> +1,125$ (2,4%)

[moneyschlampe]

Was soll man noch sagen zu den Zahlen? Zwar kein Gewinn aber wesentlich besser als erwartet.

Also Let´s go.


Tschüß

[jeninvestor]

Hallo

Nachdem es erst so aussah, als wenn die Drohung der FDA nichts am steigenden Kurs von Celgene ändern könnte, bekräftigte man heute die Forderung nach Absetzung von Thalomid und der Kurs paßte sich dem übrigen Markt an.



FDA warns Celgene about false claims for thalidomide (Reuters)

WASHINGTON, May 4 (Reuters) - Celgene Corp <CELG.O must
respond by Friday to a U.S. Food and Drug Administration
warning letter accusing the company of promoting thalidomide
as a cancer treatment without getting the FDA`s approval.
The agency sent the company a sharply-worded letter on
April 21, saying it faced regulatory action if it did not
immediately stop marketing the controversial drug for
unapproved uses and propose corrective action.
Thalidomide, a morning sickness drug that produced deformed
limbs in thousands of babies in the 1950s and 1960s, reappeared
on the U.S. market after a long hiatus in 1998, approved by the
FDA for use only in treating the inflammatory complications of
leprosy.
But the Warren, New Jersey-based company is testing
thalidomide, marketed under the brand name Thalomid, to treat a
wide range of cancers and other diseases such as rheumatoid
arthritis -- and the FDA said it has already begun marketing it
for these uses.
In November, the New England Journal of Medicine reported
that the drug had reduced, or in some cases, eliminated, tumor
activity in patients with advanced multiple myeloma, an
incurable blood cancer.
Despite that report, the FDA has not approved its use for
anything other than treating patients with leprosy.
"Perhaps more than for any other available drug, the need
to provide and distribute thalidomide responsibly is essential
to the public health," the FDA wrote in its warning letter.
It cited cases of Celgene representatives promoting the
drug for so-called "off-label" uses, such as treating myeloma,
in private meetings with oncologists and other doctors.
The FDA said this was "particularly troublesome" because
the agency had specifically instructed Celgene to avoid such
statements or implications.

Ich hoffe es wird den Kurs nicht alzu lange behindern.

MfG

[jeninvestor]

und wir fallen mit dem Nassi.....

[5404]

Hallo,

Eine positive Reaktion auf die Nasdaq hatte ich mir aber schon erhofft.
Wird aber wohl an der Forderung der FDA liegen.
Trotzdem, die Zukunftsaussichten sind hervorragend.
Mich würden dreistellige Kurse in wenigen Wochen, ein positiver Gesamtmarkt vorausgesetzt, nicht wundern.

mfg

5404

[jeninvestor]

Nu halt mal die Luft an. Du träumst doch. Ein Anstieg bis ins dreistellige ist zur Zeit mehr als unrealistisch.
Laß uns erstmal das High bei 62$ wieder sehen, dann können wir über weiteres spekulieren.

Hier was neues für alle:

Celgene hat das umstrittenne Patent an Novartis weitergegeben.


Elite Pharmaceuticals, Inc. Completes Manufacturing Facility
NORTHVALE, N.J., May 11, 2000 /PRNewswire via COMTEX/ -- Elite
Pharmaceuticals, Inc, (Amex: ELI; OTC Bulletin Board: ELIPZ) has completed
construction and equipment installation in its state-of-the-art manufacturing
facility in Northvale, New Jersey. This facility will accommodate the
manufacturing of pharmaceutical products in sufficient quantities to obtain FDA
approval.

U.S. Patent No. 5,837,284 related to pulse dose methylphenidate products was
recently issued to Dr. Atul M. Mehta of Elite. This patent, which was
exclusively licensed to Celgene Corporation (Nasdaq: CELG), has now been
licensed by Celgene to Novartis. The product simulates two doses of the drug
marketed as Ritalin(R). Elite retains certain manufacturing rights for this
product. It has also retained rights to its pulse dose technology as it relates
to all non-methylphenidate drugs.

Elite specializes in the development of oral drug delivery products. These
include delayed release, sustained release, targeted release, pulse dose, and
other controlled release formulations, including taste masking. Recent patents
issued to Dr. Mehta of Elite relate to nifedipine formulations and method of
preparation (U.S. Patent Nos. 8,871,776 and 5,902,632).

This release contains certain forward-looking statements which involve known and
unknown risks, delays, uncertainties and other factors not under the Company`s
control which may cause actual results, performance or achievements of the
Company to be materially different from the results, performance or other
expectations implied by these forward-looking statements. These factors include
results of current or pending research and development activities, actions by
the FDA and other regulatory authorities, and those factors detailed in the
Company`s filings with the Securities and Exchange Commission such as 10K, 10Q
and 8K reports.


MfG

[jeninvestor]

Hallo zusammen.

Eigentlich gibt es gute Nachrichten für Celgene, aber da der Markt "etwas" nach unten geht.
Naja, seht selber.


The Scourge of Cancer (Muscle Wasting) Can Now Be Accurately Detected By Xitron Technologies` Device Wasting Affects the Quality of Life of 80% of Cancer Patient and Kills 30%

SAN DIEGO, May 22, 2000 /PRNewswire via COMTEX/ -- Scientists at the John Wayne
Cancer Institute reported Saturday at the American Society of Clinical Oncology
Conference in New Orleans that according to Xitron`s device, cancer patients
with stage IV malignant disease given Thalidomide (Celgene, Inc.) did not lose
muscle mass. These are important findings because the loss of muscle mass (that
is, body protein) is closely associated with quality of life, complications,
response to chemotherapy and death. Body weight is now used to measure wasting
but provides no information as to the actual body compartment being affected
(fat, water, protein or bone). A wasting patient with fluid accumulation (edema)
could have little or no weight loss. Xitron`s device accurately measures
intracellular water (ICW), which decreases when body protein is lost. The device
is based upon a technology called bioimpedance spectroscopy that Xitron (San
Diego, CA) has been developing since the early 1990`s. Xitron`s bioimpedance
device was recently selected for the National Health and Examination Survey
conducted every decade by the U. S. Centers for Disease Control.

Xitron`s device will have a major impact on patient diagnosis and care because
it is accurate, noninvasive, easy to use and inexpensive. Wasting is effectively
malnutrition and is a major medical problem. Malnutrition reduces patient
physical ability and immune function. A reduced immune function makes wounds
harder to heal and increases overall susceptibility to infection. Malnutrition
is a major cause of complication and death in dialysis, AIDS and a large
percentage of hospital patients. In addition, the public is generally unaware
that most nursing home patients are malnourished, many severely. This was in
part due to the lack of an accurate, reliable and affordable method for
routinely determining patient nutritional status. This is no longer the case.

Only Xitron`s patented measurement technology can accurately measure ICW and
effectiveness of the various therapies being developed to combat wasting. Many
companies have or are developing drugs, appetite stimulants, nutritional
products, growth hormone and anabolic steroids to combat the loss of muscle mass
caused by malnutrition. Increasing or maintaining muscle mass should also be a
primary goal of an effective exercise or weight loss program. The validity of
Xitron`s measurement technology was recently reported in the Journal of Applied
Physiology and the journal AIDS. Validity studies have also been reported in the
journals Lancet, Clinical Endocrinology and Kidney International. Xitron is a
privately held company founded in 1990.

Wenn sich der Markt wieder beruhigt hat werden sie auch diese News wieder sehen.

[IWA Japan]

Im Global Biotech Investor von Anfang MAi (Der,der als Probe im AKtionär war) schrieben sie, dass dreistellige Kurse nicht utopisch sind!

[IWA Japan]

Mal schauen, wie sich CELg in den nächsten Tagen entwickelt.
Falls die Charttechnik ein positives Signal liefert, übrlegei ch mir ernsthaft, endlich auch in CEegene einzusteigen

[jeninvestor]

Guten Abend.

Schön zusehen, daß sich doch einige für Celgene interessieren. Nach den guten Nachrichten von gestern, kommt heute eine weniger gute, eher schlechte Nachricht.
Einige hohe Mitarbeiter von Celgene scheinen ihr Tafelsilber verscherbeln zu wollen.

Mist wenn nicht mal mehr die an Celgene glauben... .


Celgene CEO, president file to sell stock

WASHINGTON, May 22 (Reuters) - Celgene Corp.
Chairman John Jackson and President Sol Barer plan to sell a
total of 200,000 common shares of the biopharmaceutical
company, worth about $9 million, regulatory filings showed.
Jackson, who is also chief executive officer, filed with
the Securities and Exchange Commission on May 11, showing an
intention to unload 50,000 shares valued at $2.3 million.
Barer made a filing on the same day to sell 150,000 shares
for about $6.9 million.
They acquired the shares after exercising stock options.
Neither executive has sold any Celgene stock in the past three
months, according to the SEC filings, released on May 19.
There was no immediate comment from Celgene, based in
Warren, N.J.

Naja von sowas lassen wir uns nicht abschrecken.

[jeninvestor]

Hier mal wieder gute Nachrichten.


News June 01, 13:44 Eastern Time

Elite Pharmaceuticals and Inabata Sign MOU

NORTHVALE, N.J., Jun 1, 2000 /PRNewswire via COMTEX/ -- Elite Pharmaceuticals,
Inc, (Amex: ELI; OTC Bulletin Board: ELIPZ) and Inabata America Corporation
signed a Memorandum Of Understanding to form a joint venture in Japan and to
license and market Elite products in Japan. Elite will retain the control of the
joint venture company and contribute products and technology whereas Inabata
would provide funding and marketing support.

Elite specializes in the development of oral drug delivery products. These
include delayed release, sustained release, targeted release, pulse dose, and
other controlled release formulations, including taste masking. Recent patents
issued to Dr. Mehta of Elite relate to nifedipine formulations and method of
preparation (U.S. Patent Nos. 8,871,776 and 5,902,632) and pulse release
methylphenidate drugs (U.S. Patent 5,837,284). The latter has been licensed to
Celgene (Nasdaq: CELG) who recently licensed it to Novartis. In addition Elite
has developed to various stages several other oral controlled release products
in the therapeutic areas such as cardiovascular, anti-arthritic, antidabetic,
and CNS. Elite recently completed its manufacturing facility in Northvale, NJ
and is FDA and DEA registered.

Inabata is an international trading company involved in a variety of industries
including chemical and pharmaceuticals. Its sales exceeded $2.5 billion for
1999. Inabata is also affiliated with Sumitomo Pharmaceuticals as well as Kyoto
Pharmaceuticals. Inabata distributes its products through a network of sales
offices and affiliates worldwide. The Japanese Pharmaceutical market is
estimated at over $20 billion. Commenting on the transaction, Mr. Abe, President
of Inabata America Corp. stated, "We are pleased to have the opportunity to
introduce Elite`s sophisticated products and technology to the Japanese
pharmaceutical market place."

This release contains, certain forward-looking statements which involve known
and unknown risks, delays, uncertainties and other factors not under the
Company`s control which may cause actual results, performance or achievements of
the Company to be materially different from the results, performance or other
expectations implied by these forward-looking statements. These factors include
results of current or pending research and development activities, actions by
the FDA and other regulatory authorities, and those factors detailed in the
Company`s filings with the Securities and Exchange Commission such as 1OK, 1OQ
and 8K reports.

SOURCE Elite Pharmaceuticals, Inc.


MfG

[HelplessLolita]

Tut Tut!!

Wer jetzt noch nicht im Celgene Zug sitzt bitte aufspringen. Die rasante Fahrt kann beginnen. Erstmal auf zum Allzeit-Hoch bei 60$.

[jeninvestor]

Good News sind immer willkommen.



Celgene Announces End of FTC Waiting Period; d-Methylphenidate License Agreement with Novartis Now Effective Milestone Triggers $10 Million Payment to Celgene

WARREN, N.J., Jun 12, 2000 /PRNewswire via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its exclusive worldwide (except Canada)
license agreement with Novartis Pharma AG for the development and marketing of
d-methylphenidate, its chirally pure version of Ritalin(R), has become effective
with the expiration of the 30-day waiting period required under the
Hart-Scott-Rodino (HSR) Pre-Merger Notification Act on June 10, 2000.

"With the HSR waiting period behind us, we will quickly establish the joint
Novartis-Celgene development committee that will oversee the further development
and commercialization of this compound. This milestone triggers a $10 million
payment under the agreement. Our next major objective is to submit our New Drug
Application (NDA) in the third quarter of this year," said Sol Barer, Ph.D.,
President and Chief Operating Officer of Celgene.

Under the terms of the agreement, Celgene granted its intellectual property
rights to the chirally pure version of Ritalin and to a long acting formulation
of Ritalin. This formulation will eliminate the mid-day dose, which has been
identified by physicians, parents and school staff as a significant unmet
medical and market need.

Under the license agreement, Novartis is to fund all remaining development
required for the regulatory approval process and to cover expenses associated
with the commercialization of the product. A joint development committee will
direct the commercialization and regulatory strategies regarding the new drug
including the continuation of marketing trials to amplify its safety and
efficacy profile. As previously announced, Celgene will receive substantial
milestone payments upon submission and approval of the d-methylphenidate
products as well as royalties on all formulations of the Ritalin product line.

Celgene Corporation, headquartered in Warren, New Jersey, is an independent
biopharmaceutical company engaged in the discovery, development and
commercialization of small molecule drugs for cancer and immunological diseases.
Please feel free to visit the Company`s website at http://www.celgene.com .

This release contains certain forward-looking statements which involve known and
unknown risks, delays, uncertainties and other factors not under the Company`s
control which may cause actual results, performance or achievements of the
Company to be materially different from the results, performance or other
expectations implied by these forward-looking statements. These factors include
results of current or pending research and development activities, actions by
the FDA and other regulatory authorities, and those factors detailed in the
Company`s filings with the Securities and Exchange Commission such as 10K, 10Q
and 8K reports.

SOURCE Celgene Corporation

[jeninvestor]

Ich muß mich heut einfach mal wieder einmischen. In den anderen Diskussionen über Celgene wird darüber diskutiert Celgene rauszuschmeißen. Wieso? Wir haben das Allzeithoch überschritten und sind bis 70E gestiegen. Jetzt geht es erst einmal wieder nach unten. Eine ganz normale technische Reaktion. Na und überlegt doch mal. Vor nicht all zulanger Zeit war ein Split, der uns auf einen Stand bei 35E brachte und seht euch an was seit dem mit Celgene geschen ist. Es geht aufwärts.
In einer anderen Diskussion wird behauptet Celgene hat nur ein Medikament, daß ist einfach nur falsch. Es geht immer nur um Thalomid, welches ein überaus erfolgreiches Medikament ist. Dabei vergessen aber viele, das sich eine Vielzahl von Krebsmedikamenten in der III.Phase befinden und demnächst wohl zu gelassen werden.
Wieso also sollte man Celgene verkaufen.

Bitte Antwort auf diese Frage.

MfG

[biozocker]

celgene sollte man auf keinen fall verkaufen,eher bei kursen wie heute noch zukaufen!!
celgene hat fast 20 medikamente in der pruduktpipeline,die in den nächsten jahren auf den markt kommen.
trotzdem ist celgene thalomid abhängig,was ja auch der historische kurs wiederspiegelt.
ich bin trotzdem sehr otimistisch für den wert und kann nur raten bei diesen kursen zuzuschlagen!!
außerdem ist celgene auch positiv imaktuellen"aktionär" erwähnt,mit einem kursziel von 150 euro.

[jeninvestor]

Guten Morgen.

@biozocker: Ich habe es extra vermieden auf den "Aktionär" hinzuweisen, bei manchen hat er ein schlechtes Image, wegen Bernd "ich pusche sie alle" Förtsch.

Aber mit Celgene hast du recht. Es wird weiter nach oben gehen, auch wenn nur ein Teil der Medikamente zugelassen wird.
... und wenn die neuesten Untersuchungen mit Thalomid noch eine neue Erkenntnis bringen, wird auch das Zugpferd von Celgene wieder kräftig ziehen.

MfG

[jeninvestor]

Den nachstehenden Text hab ich aus nem anderen Thread geklaut. Nicht weiter sagen. Gute Nachrichten für alle Besitzer von Celgene.

Das biopharmazeutische Unternehmen Celgene Corp. (Nasdaq: CELG) meldete heute, dass man den Gentherapieentwickler Signal Pharmaceuticals Inc. für etwa 196 Millionen US-Dollar in Aktien erwerben werde.

Celgene wird 3,67 Millionen Aktien aus eigenem Besitz gegen alle privatgehaltenen Anteile von Signal tauschen. Das Umtauschverhältnis liegt bei 0,1257 Celgene-Aktien für eine Signal-Aktie. Dies Transaktion wird leicht negative Auswirkungen auf Celgenes Fiskaljahr 2001, aber keinen Effekt auf die Ergebnisse im Fiskaljahr 2002 haben.

Signal konzentriert sich auf die Erforschung und Entwicklung neuer Klassen von Arzneien, die direkt auf Gene, die mit einer Krankheit in Verbindung gebracht werden, einwirken. Signals Technologie basiert auf Schlüsselelementen interzellularer Verständigung und Gen- und Proteinregulierung. Celgene entwickelt und vermarktet Arzneien zur Behandlung von Krebs und Immunsystemkrankheiten.

Celgene wird mit einem Minus von 0,82 Prozent bei 53-1/16 US-Dollar gehandelt.


:-)) :-))

MfG

[biozocker]

@ jeninvestor
ich sehe die zukunft für celgene auch positiv und die übernahme ist auch eine positive nachricht!!

[jeninvestor]

Ich habe wieder ein paar News für alle.


Warren, N.J.-Based Drug Company to Buy San Diego-Based Pharmaceuticals Firm

Jul. 3 (The Star-Ledger/KRTBN)--Celgene Corp. is adding gene-gazers to its
stable of new-drug hunters, with a $190 million purchase of Signal
Pharmaceuticals Inc.

The acquisition will net the owners of closely-held Signal, based in San Diego,
nearly three times as much as the company hoped to raise with a stock offering
this spring. Signal pulled a $70 million initial public offering when the market
for high- tech stocks plunged in April.

Signal`s specialty is using its research in how genes trigger disease to find
clues for new drugs. It`s working on clues it believes can lead to treatments
for breast and prostate cancer, osteoporosis and arthritis.

Warren-based Celgene, which makes thalidomide, does its drug hunting from its
base of knowledge of particular kinds of compounds. It works, for instance on
molecules that are mirror images of one another has helped it develop a new
version of Ritalin, the medication used for attention deficit disorder.

"This a major technological diversification for us," said Celgene spokesman
Robert Hugin. Signal`s chief executive officer, Alan Lewis, said the merged
companies` pipeline of new drugs "will be competitive with the major
pharmaceutical companies."

Wall Street seemed intrigued: Celgene shares ended $5.38 higher at $58.88.

Only a handful of companies take the same approach as Signal in looking for new
medications, Hugin said. The company has more than 70 researchers and holds 38
patents, with more than 80 more pending.

Celgene is swapping 3.7 million shares of stock for Signal. The deal will give
Signal`s current owners a 4.4 percent stake in Celgene.

The deal is subject to review under the Hart-Scott-Rodino antitrust act, as well
as by Signal`s stockholders -- but owners of 56 percent of the common and 78
percent of the preferred have already agreed to the deal.

[jeninvestor]

Hallo zusammen.

Heute mache ich etwas Werbung für Celgene und für meine Homepage. Dort findet ihr alles zu Celg.

www.jeninvestor.de

Viel Spaß.

PS Wer sie nicht sehen will läßt es.